Trade Novartis - CHF - NOVN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.35
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investmentCHF 1,000.00Overnight funding adjustmentCharges from full value of position-0.01083 %(-CHF 2.17)Trade size with leverage ~ CHF 20,000.00Money from leverage ~ $CHF 19,000.00Go to platform: -0.01083%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investmentCHF 1,000.00Overnight funding adjustmentCharges from full value of position-0.01139 %(-CHF 2.28)Trade size with leverage ~ CHF 20,000.00Money from leverage ~ $CHF 19,000.00Go to platform: -0.01139%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: CHF
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: Switzerland
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: CHF 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01083 %
  (-CHF 2.17)

• Margin. Your investment: CHF 1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01139 %
  (-CHF 2.28)

Key Stats

• Prev. Close: 125.25
• Open: 124
• 1-Year Change: 19.75%
• Day's Range: 123.55 - 124.65

Trade Novartis - CHF - NOVN

Novartis AG (NVS) is a global pharmaceutical company.  Founded in 1996 through a merger of Ciba-Geigy and Sandoz, Novartis is headquartered in Basel, Switzerland. The firm has two divisions: Innovative Medicines and Sandoz.

Innovative Medicines offer prescription medicines and create treatments in areas of respiratory, ophthalmology, neuroscience, immunology, hepatology, dermatology, cardiovascular, renal and metabolism. 

Sandoz develops, manufactures and markets generic pharmaceuticals and biosimilars. Sandoz products include: Adakveo (crizanlizumab), Afinitor Disperz/Votubia (everolimus) and Arzerra (ofatumumab) for Oncology; and Aimovig (erenumab) for neuroscience. 

In 2020, in response to the pandemic, the company collaborated with Molecular Partners to develop ensovibep, a DARPin therapeutic candidate designed for potential use against Covid-19. 

The company’s shares have been listed on the New York Stock Exchange (NYSE) since 2000. Novartis AG stock is traded under the ticker symbol NVS. You can track live NVS share value and price history at Capital.com.